What if a simple blood test could help detect cancer before symptoms appear? Researchers are studying new tests designed to identify 13 types of cancer earlier, potentially giving patients a better chance of receiving timely treatment.
The trial, announced on November 4, 2026, will take place in England, where more than 20,000 patients aged 45 and above are expected to participate at over 200 health centres. The research will focus on people experiencing symptoms that may be linked to cancer but are often difficult to identify.
“Those symptoms can be misread as something else,” UK Health Minister James Frith told LBC Radio, explaining that warning signs such as persistent stomach discomfort, bloating and changes in bowel movements can sometimes be mistaken for less serious health problems.
The study, led by the University of Birmingham and supported by the National Health Service (NHS), will examine whether new blood tests can help doctors identify patients who need further cancer investigations.
The cancers being investigated include those affecting the bowel, stomach, pancreas, liver, ovaries, kidneys, bladder and prostate.
Other cancers covered by the research include those affecting the small bowel, oesophagus, bile ducts, gallbladder and lining of the womb.
The trial, known as STRIDE-RCT, will examine several blood-testing technologies, including some that use artificial intelligence to analyse information in blood samples.
Scientists hope these technologies could help doctors identify warning signs of cancer before the disease reaches a more advanced stage.
How the new blood tests work
The tests are designed to detect changes in the blood that may indicate the presence of cancer.
Some examine small fragments of DNA released into the bloodstream by cancer cells, while others measure proteins that may be associated with cancer or the body’s response to the disease.
Artificial intelligence can help analyse complex patterns in these samples and identify results that may require further medical attention.
Unlike many existing diagnostic tests that focus on a particular organ, the new methods are being studied for their ability to identify signs linked to several cancers using a single blood sample.
Most participants will provide one or two tubes of blood during a routine medical appointment.
Doctors will examine the results alongside the patient’s symptoms and medical history before deciding whether further investigations are necessary.
However, researchers have emphasised that a positive blood test does not automatically mean someone has cancer.
Additional examinations will still be needed to confirm a diagnosis. Similarly, a negative result cannot completely rule out the disease.
The trial will determine how accurately the tests work and whether they can help doctors make quicker decisions about patients who need specialised care.
Why finding cancer earlier matters
Cancer treatment is often more successful when the disease is discovered before it spreads to other parts of the body.
Some cancers, particularly those affecting organs inside the abdomen, can be difficult to identify because their early symptoms resemble common health problems.
Patients may experience stomach pain, bloating or changes in digestion without immediately realising that further medical attention is needed.
According to UK government figures, approximately 71,000 people in England are diagnosed each year with pancreatic, stomach, liver, ovarian or bowel cancer, while nearly 35,000 deaths are recorded annually from these diseases.
For bowel cancer, around nine in ten patients diagnosed at the earliest stage survive for at least five years, compared with approximately one in ten patients diagnosed at stage four.
These figures show why identifying cancer earlier remains an important goal for medical researchers.
The UK government has committed up to £8.49 million to support the trial.
Researchers will examine whether the blood tests can help doctors identify patients who require urgent investigation while reducing unnecessary referrals for people whose symptoms are caused by other conditions.
If successful, the technology could help patients receive medical attention sooner and make the process of identifying suspected cancers more efficient.
What previous research has shown
The new trial follows several years of international research into blood tests capable of detecting more than one type of cancer.
However, previous findings have also shown that promising technology must undergo careful testing before it can be introduced into routine healthcare.
A separate NHS study involving more than 142,000 people examined a blood test known as Galleri, which was designed to detect signals associated with several cancers.
Results published in 2026 showed that the test did not significantly reduce the combined number of stage-three and stage-four cancer diagnoses, meaning the study did not achieve its main objective.
Researchers nevertheless reported fewer diagnoses of the most advanced cancers during later screening rounds.
The new STRIDE-RCT trial differs from that earlier study because it focuses on patients already experiencing possible cancer symptoms, rather than screening people who do not have symptoms.
Its findings will help doctors and researchers understand whether these technologies can improve decisions about which patients should undergo further examinations.
What the research could mean for Rwanda
Although the trial is taking place in England, its findings could provide useful information for countries working to improve early cancer diagnosis, including Rwanda.
Rwanda has continued expanding cancer screening and improving how cases are recorded across health facilities.
Figures in the Ministry of Health’s 2024/2025 report show that 5,548 cancer cases were registered in 2023. The ministry attributed much of the increase in recorded cases over previous years to better diagnostic services and improvements in cancer registration.
In September 2026, a case study on Rwanda’s national cancer registry also highlighted progress in moving from paper-based records to digital reporting, allowing cancer information to be collected from health facilities across the country.
The country has also expanded programmes for early detection of cervical and breast cancers, encouraging people to seek screening and medical care before diseases become more difficult to treat.
The new blood-testing research offers another area of medical innovation that could be important for countries seeking better ways to diagnose cancer.
However, the tests are not currently available as part of routine cancer diagnosis in Rwanda, and their effectiveness has not yet been established.
Further research will be needed to determine whether the technology is reliable, affordable and suitable for wider use in different healthcare systems.
For patients, the immediate message remains the importance of seeking medical advice when unusual symptoms persist rather than waiting for them to become severe.
If the trial demonstrates that the blood tests can accurately identify people who need further investigation, the technology could eventually offer doctors another way to detect cancer earlier and improve patients’ chances of receiving timely treatment.
Elie GATETE
RADIOTV10